证券代码：300451 证券简称：创业慧康 公告编号：2025-064 创业慧康科技股份有限公司 关于 2025 年第三季度计提信用减值准备和资产减值准备 的公告 本公司及董事会全体成员保证公告的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 创业慧康科技股份有限公司（以下简称"公司"）根据《深圳证券交易所上 市公司自律监管指引第 2 号——创业板上市公司规范运作》《企业会计准则》以 及公司相关会计政策的规定，在 2025 年第三季度计提了信用减值损失及资产减 值损失，现将具体情况公告如下： 一、本次计提信用减值准备和资产减值准备情况概述 1、本次计提信用减值准备和资产减值准备的原因 根据《企业会计准则》《深圳证券交易所创业板股票上市规则》等相关规定 的要求，为真实准确地反映公司 2025 年 7 月 1 日至 2025 年 9 月 30 日的财务状 况和经营成果，公司对截至 2025 年 9 月 30 日的各类资产进行了减值测试，基于 谨慎性原则，对部分资产计提信用减值准备以及资产减值准备合计人民币 29,826,588.56 元。具体情况如下表： | | 项目 | 本期发生额（单位：元） | ...

Financial Performance - Revenue for Q3 2025 was CNY 285,009,476.73, a decrease of 35.50% year-over-year, and a decrease of 26.26% year-to-date [3]. - Net profit attributable to shareholders was a loss of CNY 41,669,455.71, down 264.20% year-over-year, and a loss of CNY 122,224,175.50 year-to-date, down 331.69% [3]. - Basic and diluted earnings per share were both CNY -0.03, reflecting a decrease of 250.00% year-over-year [3]. - Total operating revenue for the period was ¥861,687,740.98, a decrease of approximately 26.2% from ¥1,168,619,942.05 in the previous period [25]. - The net profit for the period was a loss of ¥106,750,444.48, compared to a profit of ¥58,948,817.27 in the same period last year [27]. - Total comprehensive income for the period was -107,058,105.79 CNY, compared to 58,589,463.68 CNY in the previous period [28]. - Basic and diluted earnings per share were both -0.08 CNY, down from 0.03 CNY in the previous period [28]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 5,487,658,950.00, a decrease of 3.18% compared to the end of the previous year [3]. - Total assets decreased to ¥5,487,658,950.00 from ¥5,668,132,706.72, representing a decline of approximately 3.2% [24]. - Current liabilities totaled ¥1,101,603,924.13, down from ¥1,182,115,391.60, indicating a reduction of about 6.8% [24]. - The company reported a 43.45% decrease in current liabilities due to cost reduction and office consolidation efforts [7]. - The total equity attributable to shareholders decreased to ¥4,305,619,229.60 from ¥4,419,247,940.16, reflecting a decrease of about 2.6% [24]. Cash Flow - Cash flow from operating activities year-to-date was CNY -205,443,881.78, a decrease of 1.73% [3]. - Cash inflow from operating activities was 870,344,566.09 CNY, a decrease of 6.34% from 929,389,713.78 CNY in the previous period [29]. - Net cash flow from operating activities was -205,443,881.78 CNY, slightly worse than -201,946,282.20 CNY in the previous period [29]. - Cash inflow from investing activities totaled 991,469,974.58 CNY, significantly higher than 276,760,757.45 CNY in the previous period [31]. - Net cash flow from investing activities was -82,166,120.37 CNY, an improvement from -180,504,403.53 CNY in the previous period [31]. - Cash inflow from financing activities was 59,887,766.67 CNY, compared to 7,300,000.00 CNY in the previous period [31]. - Net cash flow from financing activities was 7,375,623.38 CNY, recovering from -17,568,142.06 CNY in the previous period [31]. - The ending balance of cash and cash equivalents was 735,712,921.09 CNY, up from 687,407,670.58 CNY in the previous period [31]. - The company's cash and cash equivalents decreased to ¥736,996,627.48 from ¥1,018,894,565.64, a decline of approximately 27.7% [22]. Income and Expenses - Total operating costs amounted to ¥889,664,255.47, down from ¥1,006,634,936.64, reflecting a reduction of about 11.6% [25]. - Research and development expenses increased to ¥223,500,790.80, up 20.5% from ¥185,412,536.45 in the previous period [27]. - The company reported a significant increase in investment income to ¥4,437,239.99 from ¥1,466,654.85, marking a growth of approximately 202.5% [27]. - The company's financial expenses improved, showing a reduction to -¥5,319,288.62 from -¥30,568,333.70, indicating a positive change in financial management [27]. Operational Highlights - The company secured a total of 24 orders worth over ten million RMB, with a year-on-year increase of 20% in order quantity and 7% in order value [18]. - The company successfully completed 16 HI-HIS project launches, with 75% of these projects being in tertiary hospitals [18]. - The company faced operational pressures due to delayed customer demand and postponed bidding processes, leading to revenue contraction [18]. - The company was recognized as a "scene-based digital service provider" by the Zhejiang Provincial Economic and Information Technology Department for 2025 [18]. - The AI application for key patient tracking (APTS) was included in the 2025 "Smart Products" list in Zhejiang Province, enhancing early detection and intervention capabilities for major diseases [18]. - The company completed the core system launch for Suzhou Municipal Hospital, marking the full completion of the information project for a large medical group with 5,000 beds [19]. - The company plans to continue strengthening its development support and operational capabilities to enhance project delivery efficiency [19]. - The company is optimistic about the future, citing strong core business prospects and continuous customer demand [19]. - The company approved the 2025 employee stock ownership plan, with shares sourced from the company's repurchase account for A-shares [19]. Other Information - Cash received from tax refunds increased by CNY 7,196,400.00 year-over-year, mainly due to an increase in VAT refunds [9]. - Cash paid for fixed assets decreased by 38.19% year-over-year, due to the completion of a project in the previous year [10]. - The third quarter financial report was not audited [32].

Core Viewpoint - The stock of Chuangye Huikang (300451) has shown a recent increase in price and trading activity, with significant net inflows from institutional and retail investors, despite a decline in financial performance year-over-year [1][2][5]. Financial Performance - Chuangye Huikang reported a main revenue of 577 million yuan for 2025, a year-on-year decrease of 20.65% [5] - The net profit attributable to shareholders was -80.55 million yuan, representing a year-on-year decline of 394.25% [5] - The second quarter of 2025 saw a single-quarter main revenue of 286 million yuan, down 18.48% year-on-year [5] - The company has a debt ratio of 20.5% and a gross profit margin of 51.45% [5] Stock Performance and Trading Activity - As of October 23, 2025, the stock closed at 4.72 yuan, up 3.28% with a trading volume of 419,000 hands and a total transaction amount of 194 million yuan [1] - Over the past five days, the stock has experienced fluctuations in net capital inflows, with a net inflow of 443.58 million yuan from main funds on October 23 [2][3] - The financing balance stood at 489 million yuan on October 23, with a net financing purchase of 6.54 million yuan [3] Industry Comparison - Chuangye Huikang's total market value is 7.312 billion yuan, compared to the software development industry average of 13.129 billion yuan [5] - The company has a price-to-earnings ratio of -45.38, while the industry average is 88.08 [5] - The net profit margin for Chuangye Huikang is -12.54%, slightly worse than the industry average of -12.34% [5] Institutional Ratings - In the last 90 days, four institutions have rated the stock as a buy, with an average target price of 6.37 yuan [6]

Policy Developments - Liaoning Province will implement direct payment of maternity allowances to employees starting November 1, 2025, enhancing convenience and satisfaction for the public [1] Drug and Device Approvals - Hengrui Medicine's subsidiary received clinical trial approval for injection of Rukang Qutuzumab, aimed at treating advanced non-small cell lung cancer [2] - Jibeier received approval for the market application of the chemical raw material drug, Gatifloxacin, which is expected to support its production needs [3] Financial Reports - Ping An Good Doctor reported a 13.6% increase in revenue to 3.725 billion, with a net profit of 216 million, up 45.7% year-on-year [4] - Te Yi Pharmaceutical achieved a 985% increase in net profit, reporting 65.22 million in the first three quarters, with significant growth in traditional Chinese medicine sales [5] - Lijun Pharmaceutical reported a revenue of 9.116 billion, a slight increase of 0.38%, with a net profit of 1.754 billion, up 4.86% [6] Capital Market - In Shanghai's Baoshan District, 17 key biopharmaceutical projects were signed, with total investments exceeding 2 billion, aimed at enhancing the local biopharmaceutical industry [7][8] Industry Developments - Baiyang Pharmaceutical signed a cooperation agreement with Peking University International Hospital to establish a radiosurgery treatment center, enhancing access to high-quality medical resources [10] - Qiang Brain Technology established a new company in Chengdu focusing on AI-related businesses, including medical devices and internet data services [11] Regulatory Actions - The Shanghai Stock Exchange issued a regulatory warning to Zhejiang Dongya Pharmaceutical for discrepancies in the use of raised funds, highlighting the responsibility of the company's former board secretary [12]

Core Viewpoint - Philips Medical Equipment (Shanghai) Co., Ltd. has acquired 117,698,823 unrestricted shares of Chuangye Huikang, representing 7.62% of the total share capital, for approximately 480 million yuan [1] Summary by Relevant Categories Share Acquisition - Philips Medical Equipment (Shanghai) Co., Ltd. has completed an agreement to acquire shares from Philips (China) Investment Co., Ltd. [1] - The total transaction price for the share acquisition is approximately 480 million yuan [1] - Following this transaction, Philips Medical Equipment will become a significant shareholder in Chuangye Huikang with a holding of 7.62% [1] Regulatory Compliance - The share transfer is subject to compliance confirmation from the Shenzhen Stock Exchange [1] - An application for the transfer of shares must be submitted to the Shenzhen branch of China Securities Depository and Clearing Co., Ltd. [1] Future Plans - Philips Medical Equipment (Shanghai) Co., Ltd. does not have any specific plans to increase or decrease its shareholding in the listed company within the next 12 months [1]

Core Viewpoint - The stock of Chuangye Huikang (300451) has shown a decline in both price and financial performance, with significant net losses reported in recent financial statements [1][3]. Financial Performance - As of October 22, 2025, Chuangye Huikang's stock closed at 4.57 yuan, down 0.22% with a trading volume of 20.59 million shares and a total transaction value of 94.24 million yuan [1]. - The company reported a total revenue of 577 million yuan for the first half of 2025, a year-on-year decrease of 20.65%, and a net profit attributable to shareholders of -80.55 million yuan, a decline of 394.25% [3]. - The second quarter of 2025 saw a single-quarter revenue of 286 million yuan, down 18.48% year-on-year, and a net profit of -64.91 million yuan, a decrease of 532.25% [3]. Market Position and Ratios - Chuangye Huikang's total market capitalization is 7.079 billion yuan, compared to the software development industry average of 13.037 billion yuan, ranking 85th out of 194 companies [3]. - The company has a negative price-to-earnings ratio of -43.94 and a price-to-book ratio of 1.63, which is significantly lower than the industry average of 82.2 and 7.16, respectively [3]. - The gross margin stands at 51.45%, higher than the industry average of 44.51%, while the net margin is -12.54%, slightly worse than the industry average of -12.3% [3]. Investment Sentiment - In the last 90 days, four institutions have rated the stock as a buy, with an average target price of 6.37 yuan [4].

Group 1 - The core point of the article is that Chuangye Huikang (SZ 300451) announced a share transfer agreement where Philips Investment will transfer approximately 118 million shares (about 7.62% of the total share capital after excluding repurchased shares) to Philips Medical Equipment, which is under the same controlling entity [1] - The share transfer does not trigger a mandatory tender offer as it is a transfer between different entities under the same control [1] - As of the report, Chuangye Huikang's market capitalization is 7.1 billion yuan [1] Group 2 - For the first half of 2025, Chuangye Huikang's revenue composition shows that the medical industry accounts for 94.1%, while other businesses account for 5.9% [1]

Core Viewpoint - Philips Investment, a major shareholder of Chuangyi Huikang, has signed a share transfer agreement with Philips Medical Devices to transfer 118 million unrestricted circulating shares, representing 7.620876% of the total share capital after excluding repurchased shares, at a price of 4.08 RMB per share, totaling 480 million RMB [1] Summary by Category Share Transfer Details - The share transfer involves 118 million shares from Philips Investment to Philips Medical Devices [1] - The transfer price is set at 4.08 RMB per share, amounting to a total of 480 million RMB [1] - Philips Medical Devices is restricted from selling the acquired shares within twelve months after the transfer is completed [1] Compliance and Uncertainty - The transfer is subject to compliance confirmation by the Shenzhen Stock Exchange [1] - The share transfer will require registration procedures at the Shenzhen branch of China Securities Depository and Clearing Co., Ltd, indicating potential uncertainties in the process [1]

创业慧康科技股份有限公司 简式权益变动报告书 上市公司:创业慧康科技股份有限公司 上市地点:深圳证券交易所 股票简称:创业慧康 股票代码: 300451 信息披露义务人:飞利浦(中国)投资有限公司 住所:上海市静安区灵石路 718 号 A1 幢 通讯地址:上海市静安区灵石路 718 号 A1 幢 股份变动性质: 股份减少 签署日期: 二〇二五年十月二十一日 六、本次权益变动事项尚需取得深圳证券交易所的合规确认及向中国证券登 记结算有限责任公司深圳分公司申请办理股份转让过户登记。本次权益变动是否 能通过相关部门审批存在一定的不确定性,敬请广大投资者注意投资风险。 2 目 录 l rig 信息披露义务人声明 本部分所述词语或简称与本报告书"释义"所述词语或简称具有相同含义。 一、本报告书系依据《中华人民共和国证券法》《上市公司收购管理办法》 和《公开发行证券的公司信息披露内容与格式准则第 15 号 -- 权益变动报告书》 等法律、法规及规范性文件编制。 二、信息披露义务人签署本报告书已获得必要的授权和批准,其履行亦不违 反信息披露义务人章程或内部规则中的任何条款,或与之冲突。 三、依据《中华人民共和国证券法》《上 ...

证券代码：300451 证券简称：创业慧康 公告编号：2025-062 创业慧康科技股份有限公司 关于持股5%以上股东协议转让公司股份暨权益变动的提示 性的公告 持股 5% 以上股东飞利浦（中国）投资有限公司保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 重要内容提示： 1、创业慧康科技股份有限公司（以下简称"公司"）持股5%以上股东飞 利浦（中国）投资有限公司（以下简称"飞利浦投资"）与飞利浦医疗器械(上 海)有限公司(以下简称"飞利浦医疗器械")签订了《关于创业慧康科技股份有 限公司之股份转让协议》，拟通过协议转让的方式，将持有的公司无限售条件 流通股117,698,823股(占剔除回购专用账户股份后总股本的7.620876%)转让给飞 利浦医疗器械。 2、本次协议转让股份不触及要约收购。公司无控股股东、无实际控制人， 对公司生产经营、公司治理等方面不会产生影响。 3、若本次股份协议转让事项顺利完成，则受让方飞利浦医疗器械在协议转 让完成后的十二个月内将不减持本次交易所受让的公司股份。 4、本次股份协议转让尚需 ...